<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018861</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 50465-101 (CITADEL-101)</org_study_id>
    <secondary_id>Parsaclisib</secondary_id>
    <nct_id>NCT02018861</nct_id>
  </id_info>
  <brief_title>A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to&#xD;
      find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor,&#xD;
      parsaclisib, as monotherapy and in combination with: itacitinib (INCB039110), a JAK1&#xD;
      inhibitor; rituximab; and rituximab, ifosfamide, carboplatin, and etoposide. Parsaclisib&#xD;
      inhibits PI3Kδ, a protein involved in growth and survival of B-cell cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2016</start_date>
  <completion_date type="Actual">April 12, 2021</completion_date>
  <primary_completion_date type="Actual">April 12, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessed by summary of Adverse Events (AEs), clinical lab assessments, physical exam results, and 12-lead ECGs for Parsaclisib as monotherapy and as a combination therapy</measure>
    <time_frame>Measured every 3 weeks for approximately 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by overall response rate</measure>
    <time_frame>Measured every 9 weeks for approximately 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic collections to determine Cmax, Tmax, Cmin, half-life</measure>
    <time_frame>Measured for each patient at Day 1, Day 8, and Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>B-Cell Malignancies</condition>
  <arm_group>
    <arm_group_label>Parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating doses given every day (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parsaclisib in combination with itacitinib (INCB039110)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of parsaclisib determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of parsaclisib determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parsaclisib</intervention_name>
    <arm_group_label>Parsaclisib</arm_group_label>
    <arm_group_label>Parsaclisib in combination with itacitinib (INCB039110)</arm_group_label>
    <arm_group_label>Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itacitinib</intervention_name>
    <arm_group_label>Parsaclisib in combination with itacitinib (INCB039110)</arm_group_label>
    <other_name>INCB039110</other_name>
    <other_name>itacitinib (INCB039110)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <arm_group_label>Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <arm_group_label>Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older, with lymphoid malignancies of B-cell origin including:&#xD;
&#xD;
               1. Indolent / aggressive B-cell non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
                    -  EXCLUDING: Burkitt's lymphoma and precursor B lymphoblastic&#xD;
                       leukemia/lymphoma&#xD;
&#xD;
                    -  INCLUDING: any non-Hodgkin's B cell malignancy such as chronic lymphocytic&#xD;
                       leukemia (CLL) and rare non-Hodgkin's B- cell subtypes such as hairy cell&#xD;
                       leukemia, Waldenström macroglobulinemia (WM), mantle cell leukemia (MCL),&#xD;
                       and transformed NHL histologies&#xD;
&#xD;
               2. Hodgkin's lymphoma (HL)&#xD;
&#xD;
          -  Life expectancy of 12 weeks or longer&#xD;
&#xD;
          -  Subject must have received ≥ 1 prior treatment regimen(s)&#xD;
&#xD;
          -  The subject must not be a candidate for potentially curative therapy including&#xD;
             hematopoietic stem cell transplantation, except where one of the standard therapy&#xD;
             regimen combinations may be used prior to transplantation per standard medical&#xD;
             practice&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has history of brain metastasis, spinal cord compression (unless treated,&#xD;
             asymptomatic, and stable on most recent imaging and enrolling in expansion cohort), or&#xD;
             lymphoma involving the central nervous system (CNS)&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3 (≥ 2 during&#xD;
             dose escalation)&#xD;
&#xD;
          -  Received allogeneic hematopoietic stem cell transplant within the last 6 months, or&#xD;
             has active graft versus host disease (GVHD) following allogeneic transplant, or&#xD;
             currently receiving immunosuppressive therapy following allogeneic transplant&#xD;
&#xD;
          -  Received autologous hematopoietic stem cell transplant within the last 3 months&#xD;
&#xD;
          -  Inadequate marrow reserve assessed by hematologic laboratory parameters&#xD;
&#xD;
          -  Inadequate renal or liver function&#xD;
&#xD;
          -  Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or&#xD;
             at risk for HBV reactivation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Corrado, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama At Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyu Langone Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

